Echinocandin antifungal drugs in fungal infections: A comparison

Drugs

Volumn 71, Issue 1, 2011, Pages 11-41

  Chen, Sharon C A ^a   Slavin, Monica A ^b   Sorrell, Tania C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CALCINEURIN INHIBITOR; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN; DEXAMETHASONE; EFAVIRENZ; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; NIFEDIPINE; PHENYTOIN; RAPAMYCIN; RIFAMPICIN; TACROLIMUS;

ACUTE KIDNEY FAILURE; AMINO ACID SUBSTITUTION; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; BIOFILM; BRONCHOSPASM; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CASE REPORT; CHILD; CREATININE BLOOD LEVEL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; FEVER; FLUSHING; FUNGUS ISOLATION; HEADACHE; HEALTH CARE COST; HUMAN; HYPOKALEMIA; IN VITRO STUDY; INFECTION PREVENTION; INTRAVASCULAR HEMOLYSIS; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LACTATION; LIVER FAILURE; LIVER TOXICITY; LOADING DRUG DOSE; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA; NEUTROPENIA; NONHUMAN; PEDIATRICS; PHARMACODYNAMICS; PICHIA GUILLIERMONDII; PLASMA CONCENTRATION-TIME CURVE; PREGNANCY; PRURITUS; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SWELLING; THROMBOPHLEBITIS; TREATMENT INDICATION; URTICARIA;

ANTIFUNGAL AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ECHINOCANDINS; HUMANS; MYCOSES;

ASPERGILLUS; CANDIDA; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; PICHIA GUILLIERMONDII;

EID: 78650808399     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11585270-000000000-00000     Document Type: Review

References (205)

1. Pfaller MA, Diekema DJ. Epidemiology of invasive can-didiasis: a persistent public health problem. Clin Micro-biol Rev 2007; 20: 133-63.
2. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoie-tic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091-100.
3. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult haemato-poetic stem cell transplant recipients: analysis of multi-centre Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48: 265-73.
4. Chen SC, Slavin M, Nguyen Q, et al. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006; 12: 1508-16.
5. Morgan J. Global trends in candidemia: review of reports from 1995-2005. Curr Infect Dis Rep 2005; 7: 429-39.
6. Sipsas NV, Lewis RE, Tarrand J, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007). Cancer 2009; 115: 4745-52.
7. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-93.
8. Zonios DI, Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med 2008; 29: 198-210.
9. Brueggeman RJM, Alffenaar J-W, Bliijlevens NMA, et al. clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 1441-58.
10. Masuerkar PS, Fountoulakis JM, Hallada TC, et al. Pneumocandins from Zalerion arboricola, II: modification of product spectrum by mutation and medium manipulation. J Antibiot (Tokyo) 1992; 45: 1867-74.
11. Cancidas (caspofungin) [package insert]. Whitehouse Sta-tion (NJ): Merck & Co. Inc., 2009 Jul.
12. Eraxis (anidulafungin) [package insert]. New York: Pfizer, 2009 Jun.
13. Mycamine (micafungin) [package insert]. Deerfield (IL): Astella Pharma US, Inc., 2008 Jan.
14. Pappas PG, Kauffman CA, Andes D, et al. Clinical prac-tice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
15. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society ofAmerica. Clin Infect Dis 2008; 46: 327-60.
16. Boucher H, Groll A, Chiou C, et al. Newer systemic anti-fungal agents: pharmacokinetics, safety and efficacy. Drugs 2004; 64: 1997-2020.
17. Kauffman CA, Carver PL. Update on echinocandin anti-fungals. Semin Respir Crit Care Med 2008; 29: 211-20.
18. Sucher AJ, Chahine EB, Balcer HE, et al. Echinocandins: the newest class of antifungals. Ann Pharmacother 2009; 43: 1947-57.
19. Eschenauer G, DePestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Management 2007; 3: 71-97.
20. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51.
21. Wagner C, Graninger W, Presterl E, et al. Echinocandins: comparison of their pharmacokinetics, pharmacodynam-ics and clinical applications. Pharmacology 2006; 78: 161-77.
22. VandenBussche HL, Van Loo DA. A clinical review of echinocandins in pediatric patients. Ann Pharmacother 2010; 44: 166-77.
23. Chandrasekar PH, Sobel JD. Micafungin: a new echino-candin. Clin Infect Dis 2006; 42: 1171-8.
24. Vazquez JA, Sobel JA. Anidulafungin: a novel echino-candin. Clin Infect Dis 2006; 43: 215-22.
25. Mikamo H, Sato Y, Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipo-peptide. J Antimicrob Chemother 2000; 46: 485-7.
26. Bal AM. The echinocandins: three useful choice or three too many? Int J Antimicrob Agents 2010; 35: 13-8.
27. Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 2009; 53: 112-22.
28. Wiederhold NP, Lewis II JS. The echinocandin mica-fungin: review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother 2007; 8: 1155-66.
29. Maligie MA, Selitrennikoff CP. Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob Agents Chemother 2005; 49: 2851-6.
30. De la Torre P, Reboli AC. Anidulafungin: a new echino-candin for candidal infections. Expert Rev Infect Ther 2007; 5: 45-52.
31. Pacetti SA, Gelone SP. Caspofungin acetate for treatment of invasive fungal infection. Ann Pharmacother 2003; 37: 90-8.
32. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts. M27-A3. 3rd ed. Wayne (PA): Clinical Laboratory Standards Institute, 2008.
33. Arendrup MC, Garcia-Effron G, Lass-Florl C, et al. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1 CLSI M27-A3, E test, disk diffusion, and agar dilution methods with RPMI and IsoSensitest media. Antimicrob Agents Chemother 2010; 54: 426-39.
34. Rodriguez-Tudela JL, Arendrup MC, Barchiesi F, et al. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008; 14: 398-405.
35. Chryssanthou E, Cuenca-Estrella M. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol 2002; 40: 3841-4.
36. Wiederhold NP, Grabinski JL, Garcia-Effron G, et al. Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. Antimicrob Agents Chemother 2008; 52: 4145-8.
37. Pfaller MA, Boyken L, Hollis RJ, et al. Wild-type MIC distributions and epidemiological cutoff values (ECVs) for the echinocandins and Candida spp. J Clin Microbiol 2010; 48: 52-6.
38. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008; 46: 2620-9.
39. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
40. Garcia-Effron G, Lee S, Park S, et al. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother 2009; 53: 3690-9.
41. Pfaller MA, Castanheira M, Diekema DJ, et al. Compar-ison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J Clin Microbiol 2010; 48: 1592-9.
42. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro suscepti-bility of invasive isolates of Candida spp. to anidula-fungin, caspofungin, and micofungin: six years of global surveillance. J Clin Microbiol 2008; 46: 150-6.
43. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro suscepti-bilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006; 44: 760-3.
44. Antachopoulos C, Meletiadis J, Sein T, et al. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Asper-gillus conidia. Antimicrob Agents Chemother 2008; 52: 321-8.
45. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro suscepti-bility of clinical isolates of Aspergillus spp. to anidula-fungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J Clin Microbiol 2009; 47: 3323-5.
46. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp. including 315 isolates resistant to flucona-zole. J Clin Microbiol 2005; 43: 5425-7.
47. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008; 56: 126-9.
48. Blyth CC, Chen SC, Slavin M, et al. Not just little adults: candidemia epidemiology, molecular characterisation and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 2009; 123: 1360-8.
49. Wiederhold NP, Najvar L, Bocanegra R, et al. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother 2007; 51: 1616-20.
50. Paderu P, Garcia-Effron G, Balashov S, et al. Serum dif-ferentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 2007; 51: 2253-6.
51. Zaas AK, Alexander BD. Echinocandins: role in antifungal therapy. Expert Opin Pharmacother 2005; 6: 1657-68.
52. Ostrosky-Zeichner J, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003; 47: 3149-54.
53. Espinel-Ingroff A. In vitro antifungal activities of anidula-fungin and micafungin, licensed agents and the in-vestigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20: 121-36.
54. Ghannoum MA, Chen A, Buhari M, et al. Differential in vitro activity of anidulafungin, caspofungin and mica-fungin against Candida parapsilosis isolates recovered from a burn unit. Clin Microbiol Infect 2009; 15: 274-9.
55. Cota J, Carden M, Graybill JR, et al. In vitro pharmaco-dynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemo-ther 2006; 50: 3926-8.
56. Van Asbeck E, Clemons KA, Martinez M, et al. Significant differences in drug susceptibility among species in the Candida parapsilosis. Diagn Microbiol Infect Dis 2008; 62: 106-9.
57. Ostrosky-Zeichner L, Paetznick VL, Rodriguez J, et al. Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and serum (1,3)-B-D-glucan levels. Antimicrob Agents Chemother 2009; 53: 1639-41.
58. Kartsonis NA, Killar J, Mixson L, et al. Caspofungin sus-ceptibility testing of isolates from patients with esopha-geal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Che-mother 2005; 49: 3616-23.
59. Barchiesi F, Spreghini E, Tomassetti S, et al. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimcirob Agents Chemother 2006; 50: 2719-27.
60. Kim R, Khachikian D, Reboli AC. A comparative eval-uation of properties and clinical efficacy of the echino-candins. Expert Opin Pharmacother 2007; 8: 1479-92.
61. Ikeda F, Saika T, Sato Y, et al. Antifungal activity of mi-cafungin against Candida and Aspergillus spp. isolated from pediatric patient in Japan. Med Mycol 2009; 47: 145-8.
62. Douglas CM. Understanding the microbiology of the As-pergillus cell wall and the efficacy of caspofungin. Med Mycol 2006; 44 Suppl. 1: 95-9.
63. Bowman JC, Abruzzo GK, Flattery AM, et al. Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans. Antimicrob Agents Chemother 2006; 50: 420-5.
64. Roberts J, Schock K, Mariono S, et al. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY30366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 3381-8.
65. Ruiz-Cendoya M, Rodriguez MM, Marine M, et al. In vitro interactions of itraconazole and micafungin against clinically important filamentous fungi. Int J Antimicrob Agents 2008; 32: 418-20.
66. Petraitis V, Petraitiene R, Hope WW, et al. Combination therapy in treatment of experimental pulmonary asper-gillosis: in vitro and in vivo correlations of the concentration-and dose-dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother 2009; 53: 2382-91.
67. Demchok JP, Meletiadis J, Roilides E, et al. Comparative pharmacodynamic interaction analysis of triple combinations of capsofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp. Mycoses 2010; 53: 239-45.
68. Kahn JN, Hsu MJ, Racine F, et al. Caspofungin suscepti-bility in Aspergillus and non-Aspergillus moulds: inhibition of glucan synthase and reduction of beta-D-1,3 glu-can levels in culture. Antimicrob Agents Chemother 2006; 50: 2214-6.
69. Shalit I, Shadkchan Y, Mircus G, et al. In vitro synergy of caspofungin with licensed and novel antifungal drugs against clinical isolates of Fusarium spp. Med Mycol 2009; 47: 457-62.
70. Ramage G, Bachmann S, Patterson TF, et al. Investiga-tions of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 2002; 49: 973-80.
71. Mukherjee PK, Chandra J. Candida biofilm resistance. Drug Resist Updat 2004; 7: 301-9.
72. Kuhn DM, George T, Chandra J, et al. Antifungal suscep-tibility of Candida biofilms: unique efficacy of amphoteri-cin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773-80.
73. Choi HW, Shin JH, Jung SL, et al. Species-specific differ-ences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals. Anti-microb Agents Chemother 2007; 51: 1520-3.
74. Cocuaud C, Rodier MH, Daniault G, et al. Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms. J Antimicrob Chemother 2005; 56: 507-12.
75. Lazzeli AL, Chatuverdi AK, Pierce CG, et al. Treatment and prevention of Candida albicans biofilms with caspo-fungin in a novel central venous catheter murine model of candidiasis. J Antimicrob Chemother 2009; 64: 567-70.
76. Jacobson MJ, Piper KE, Nguyen G, etal. In vitro activity of anidulafungin against Candida albicans biofilms. Anti-microb Agents Chemother 2008; 52: 2242-3.
77. Pfaller MA, Boyken L, Hollis RJ, et al. Global surveillance of in vitro activity of micafungin against Candida: a comparison with CLSI-recommended methods. J Clin Mi-crobiol 2006; 44: 3533-8.
78. Pfaller MA, Diekma DJ, Gibbs DL, et al. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK antifungal surveillance program, 2001-2005. J Clin Microbiol 2008; 46: 842-9.
79. Kofteridis DP, Lewis RE, Kontoyiannis DP. Caspofungin-non-susceptible Candida isolates in cancer patients. J Antimicrob Chemother 2010; 65: 293-5.
80. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drugs Res Update 2007; 10: 121-30.
81. Miller CD, Lomaestro BW, Park S, et al. Progressive eso-phagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacother 2006; 26: 877-80.
82. Pasquale T, Tomada JR, Ghannoum MA, et al. Emergence of Candida tropicalis resistant to caspofungin [letter]. J Antimicrob Agents Chemother 2008; 61: 219.
83. Moudgal V, Little T, Boikov D, et al. Multiechinocandin-and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005; 49: 767-9.
84. Krogh-Madsen M, Arendrup M, Heslet L, et al. Ampho-tericin B and caspofungin resistance to Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006; 42: 938-44.
85. Niimi K, Monk BC, Hirai A, et al. Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity. J Anti-microb Chemother 2010; 65: 842-52.
86. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida al-bicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006; 50: 2058-63.
87. Pfeiffer CD, Garcia-Effron G, Zaas AK, et al. Break-through invasive candidiasis in patients on micafungin. J Clin Microbiol 2010; 48: 2373-80.
88. Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida spp. isolates. Antimicrob Agents Chemother 2005; 49: 3264-73.
89. Cota JM, Grabinski JL, Talbert RL, et al. Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin. Antimicrob Agents Chemother 2008; 52: 1144-6.
90. Schuetzer-Muehlbauer M, Willinger B, Krapf G, et al. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Mi-crobiol 2003; 48: 225-35.
91. Paderu P, Park S, Perlin DS. Caspofungin uptake is medi-ated by a high-affinity transporter in Candida albicans. Antimicrob Agents Chemother 2004; 48: 3845-9.
92. Gardiner RE, Souteropoulos P, Park S, et al. Character-isation of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med Mycol 2005; 43 Suppl. 1: S299-305.
93. Van Duin D, Casadevall A, Nosanchuk JD. Melanisation of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspo-fungin. Antimicrob Agents Chemother 2002; 46: 3394-400.
94. Wiederhold NP. Paradoxical echinocandin activity: a lim-ited in vitro phenomenon? Med Mycol 2009; 47 Suppl. 1: S369-75.
95. Stevens DA, White TC, Perlin DS, et al. Studies of the paradoxical effect of caspofungin at high concentrations. Diagn Microbiol Infect Dis 2005; 51: 173-8.
96. Stevens DA, Ichinomiya M, Koshi Y, et al. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother 2006; 50: 3160-1.
97. Wiederhold NP, Kontoyiannis DP, Prince RA, et al. At-tenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother 2005; 49: 5146-8.
98. Chamilos G, Lewis RE, Albert N, et al. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin- specific and Candida species-related differences. Antimicrob Agents Chemother 2007; 51: 2257-9.
99. Petriatiene R, Petraitis V, Groll A, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharma-cokinetic, drug disposition, and relationship to galacto-mannan antigenemia. Antimicrob Agents Chemother 2002; 46: 12-23.
100. Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharma-codynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190: 1464-71.
101. Clemons K, Espiritu M, Parmar R, et al. Assessment of the paradoxical effect of caspofungin therapy of candidiasis. Antimicrob Agents Chemother 2006; 50: 1293-7.
102. Dowell JA, Stogniew M, Krause D, et al. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol 2007; 47: 461-70.
103. Sobel JD, Bradshaw SK, Lipka CJ, et al. Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis 2007; 44: e46-9.
104. Sandhu P, Lee W, Xu X, et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 2005; 33: 676-82.
105. Dowell JA, Stogniew M, Krause D, et al. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005; 45: 227-33.
106. Farowski F, Cornely OA, Vehreschild JJ, et al. Quantita-tion of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 2010; 54: 1815-9.
107. Nicasio AM, Tessier PR, Nicolau DP, et al. Bronchopul-monary disposition of micafungin in healthy adult volunteers. Antimicrob Agents Chemother 2009; 53: 1218-20.
108. Nguyen TH, Hoppe-Tichy T, Geiss HK, et al. Factors in-fluencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother 2007; 60: 100-6.
109. Gumbo T, Hiemenz J, Ma L, et al. Population pharmaco-kinetics of micafungin in adult patients. Diagn Microbiol Infect Dis 2008; 60: 329-31.
110. Hebert MF, Smith HE, Marbury TC. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 2005; 45: 1145-52.
111. Walsh TJ, Admason PC, Seibel NL, et al. Pharmacokinet-ics, safety and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49: 4536-45.
112. Neely M, Jafri HS, Seibel NL, et al. The pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother 2009; 53: 1450-6.
113. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Che-mother 2005; 49: 3317-24.
114. Heresi GP, Gerstmann DR, Reed MD, et al. The pharma-cokinetics and safety of micafungin, a novel echinocandin in premature infants. Pediatr Infect Dis J 2006; 25: 1110-5.
115. Hope WW, Seibel NL, Schwartz CL, et al. Population pharmacokinetics of micafungin in paediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 2007; 51: 3714-9.
116. Hope WW, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010; 54: 2633-7.
117. Benjamin DK, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimcirob Agents Chemother 2006; 50: 632-8.
118. Pound MW, Townsend ML, Drew RH. Echinocandin pharmacodynamics: review and clinical implications. J Antimicrob Chemother 2010; 65: 1108-18.
119. Ernst EJ, Roling EE, Petzold R, et al. In vivo activity of micafungin (FK-463) against Candida spp.: microdilu-tion, time-kill and postantifungal effect studies. Anti-microb Agents Chemother 2002; 46: 3846-53.
120. Fleischhacker M, Radecke C, Schulz B, et al. Paradoxical growth effects of the echinocandins, caspofungin and micafungin, but not of anidulafungin on clinical isolates pf Candida albicans and C. dubliniensis. Eur J Clin Mcirobiol Infect Dis 2008; 27: 127-31.
121. Andes DR, Diekema DJ, Pfaller MA, et al. In vivo pharmacodynamics target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008; 52: 3497-503.
122. Gumbo T, Drusano GL, Liu W, et al. Once-weekly mica-fungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 2007; 51: 968-74.
123. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of mi-cafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neu-tropenic rabbits. Antimicrob Agents Chemother 2002; 46: 1857-69.
124. Lewis RE, Albert ND, Kontoyiannis DP. Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J Antimicrob Chemother 2008; 61: 1140-4.
125. Warn P, Morrissey G, Morrissey J, et al. Activity of mica-fungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 2003; 51: 913-9.
126. Andes D, Diekema DJ, Pfaller MA, et al. In vivo pharma-codynamic characterization of anidulafungin in a neu-tropenic murine candidiasis model. Antimicrob Agents Chemother 2008; 52: 539-50.
127. Nguyen KT, Ta P, Hoang BT, et al. Anidulafungin is fun-gicidal and exerts a variety of post-antifungal effects against Candida albicans, C. glabrata, C. parapsilosis and C. krusei isolates. Antimicrob Agents Chemother 2009; 53: 3347-52.
128. Groll AH, Mickiene D, Petraitiene R, et al. Pharmaco-kinetic and pharmacodynamic modelling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2002; 45: 2845-55.
129. Lewis RE. Pharmacodynamic implications for use of anti-fungal agents. Curr Opin Pharmacol 2007; 7: 491-7.
130. Ernst EJ, Kelpser ME, Pfaller MA. Postantifungal effects of echinocandins, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 2000; 44: 1108-11.
131. Clancy CJ, Huang H, Cheng S, et al. Characterising the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and post-antifungal effect experiments. Antimicrob Agents Chemother 2006; 50: 2569-72.
132. Louie A, Deziel M, Liu W, et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Che-mother 2005; 49: 5058-68.
133. Antachopoulos C, Meletiadis J, Sein T, et al. Concentra-tion-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob Agents Che-mother 2007; 51: 881-7.
134. Manavathu EK, Ramesh MS, Baskaran I, et al. A com-parative study of the post-antifungal effect (PAFE) of amphotericin B triazoles and echinocandins on Aspergil-lus fumigatus and Candida albicans. J Antimicrob Che-mother 2004; 53: 386-9.
135. Ikawa K, Namura K, Morikawa N, et al. Assessment of micafungin regimens by pharmacokinetic-pharmacody-namic analysis: a dosing strategy for Aspergillus infections. J Antimicrob Chemother 2009; 64: 840-4.
136. Roberts J, Schock K, Marion S, et al. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 3381-8.
137. Ibrahim AS, Bowman JC, Avanessian V, et al. Caspo-fungin inhibits Rhizopus oryzae 1,3-B-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005; 49: 721-7.
138. Stone JA, Migoya EM, Hickey L, et al. Potential for interaction between caspofungin and nelfinavir or rifam-picin. Antimicrob Agents Chemother 2004; 48: 4306-14.
139. Dowell JA, Stogniew M, Krause D, et al. Lack of pharma-cokinetic interaction between anidulafungin and tacroli-mus. J Clin Pharmacol 2007; 45: 305-14.
140. Dowell JA, Stogniew M, Karuse D, et al. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005; 45: 227-33.
141. Hebert ME, Townsend RW, Austin S, et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45: 954-60.
142. Hebert MF, Blough DK, Townsend RW, et al. Con-comitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45: 1018-24.
143. Mora-Duarte J, Betts R, Roststein C, et al. Caspofungin vs amphotericin B deoxycholate in the treatment of invasive candidiasis in neutropenic and non-neutropenic patients: a multicentre, randomised double-blind study. N Engl J Med 2002; 347: 2020-9.
144. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Mica-fungin versus liposomal amphotericin B for candidemia and invasive candidiasis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-24.
145. Wang W, Li Q, Hasvold L, et al. Discovery, SAR, synthe-sis, pharmacokinetic and biochemical characterisation of A-192411L a novel fungicidal lipopeptide-(I). Bioorg Med Chem Lett 2003; 13: 489-93.
146. Sable CA, Nguyen BV, Chodakewitz JA, et al. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002; 4: 25-30.
147. Van Burik J-AH, Ratnatharathorn V, Stephan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoeitic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-16.
148. Marr KA, Hachem R, Papanicolaou G, et al. Retrospective study of the hepatic safety profile of patients con-comitantly treated with caspofungin and cyclosporine A. Transpl Infect Dis 2004; 3: 110-6.
149. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. Safety of the concomitant use of capsofungin and cyclo-sporine A in patients with invasive fungal infections. Bone Marrow Transpl 2004; 34: 413-20
150. Red book 2009. Montvale (NJ): Thomas Reuters, 2009
151. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportu-nistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
152. Hiramatsu Y, Maeda Y, Fujii N, et al. Use of micafungin versus fluconazole for antifungal prophylaxis in neu-tropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol 2008; 88: 588-95.
153. Chou LS, Lewis RE, Ippoliti C, et al. Caspofungin as pri-mary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 2007; 27: 1644-50.
154. Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspo-fungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006; 50: 143-7.
155. de Fabritiis P, Spagnoli A, Di Bartolomeo P, et al. Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transpl 2007; 40: 245-9.
156. Fortun J, Martin-Davila P, Montejo M, et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation 2009; 87: 424-35.
157. Senn L, Eggimann P, Ksontini R, et al. Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. Intensive Care Med 2009; 35: 903-8.
158. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
159. Kubiak DW, Bryar JM, McDonnell AM, et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther 2010; 32: 637-48.
160. Villanueva A, Gotuzzo E, Arathoon EG, et al. A ran-domised double blind study of caspofungin versus fluco-nazole for the treatment of oesophageal candidiasis. Am J Med 2002; 113: 294-9.
161. de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005; 21: 899-907.
162. Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, ran-domised dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and can-didemia. Antimicrob Agents Chemother 2004; 48: 2021-4.
163. Arathoon EG, Gotuzzo E, Noriega LM, et al. Random-ized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and oesophageal candidiasis. Antimicrob Agents Chemother 2002; 46: 451-7.
164. Vazquez JA, Schranz JA, Clark K, et al. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr 2008; 48: 304-9.
165. Betts RF, Nucci M, Talwar D, et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48: 1676-84.
166. Pappas PG, Rotstein CMF, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93.
167. Dignan FL, Evans SO, Ethell ME, et al. An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspo-fungin first line: an effective strategy with low mortality. Bone Marrow Transplant 2009; 44: 51-6.
168. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised defini-tions of invasive fungal disease from the European Organisation for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
169. Viscoli C, Herbrecht R, Akan H, et al. An EORTC phase II study of caspofungin as first-line therapy of invasive as-pergillosis in haematological patients. J Antimicrob Che-mother 2009; 64: 1274-81.
170. Herbrecht R, Maertens J, Baila L, et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transpl 2010; 45: 1227-33.
171. Maertens J, Raad I, Petrikkos G, et al., Caspofungin Sal-vage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional anti-fungal therapy. Clin Infect Dis 2004; 39: 1563-71.
172. Hiemenz JW, Raad II, Maertens JA, et al. Efficacy of cas-pofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis 2010; 29: 1387-94.
173. Kartsonis NA, Saah AJ, Lipka CJ, et al. Salvage therapy with caspofungin for invasive aspergillosis. J Infect 2005; 50: 196-205.
174. Morrissey CO, Slavin MA, O'Reilly MA, et al. Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allo-geneic stem cell transplantation: efficacy and concomitant cyclosporin A [published erratum appears inMycoses 2008; 51 (2): 179]. Mycoses 2007; 50 Suppl. 1: 24-37.
175. Maertens J, Egerer G, Shin WS, et al. Caspofungin use in daily clinical practice for treatment of invasive aspergil-losis: results of a prospective observational registry. BMC Infect Dis 2010; 10: 182.
176. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive as-pergillosis. J Infect 2006; 53: 337-49.
177. Johnson MD, Perfect JR. Use of antifungal combination therapy: agents, order and timing. Curr Fungal Infect Rep 2010; 4: 87-95.
178. Pfizer. Anidulafungin plus voriconazole versus voriconazole for the treatment of invasive aspergillosis [Clinical Trials.gov identifier NCT00531479].USNational Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Nov 30].
179. Leather HL, Wingard JR. Is combination antifungal ther-apy for invasive aspergillosis a necessity in hematopoietic stem-cell transplant recipients? Curr Opin Infect Dis 2006; 19: 371-9.
180. Caillot D, Thiebaut A, Herbrecht R, et al. Liposomal am-photericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007; 110: 2740-6.
181. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107: 2888-97.
182. Rieger CT, Ostermann H, Kolb HJ, et al. A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in haematological cancer patients. Ann Hematol 2008; 87: 915-22.
183. Aliff TA, Maslak PG, Jurcic JG, et al. Refractory asper-gillus pneumonia in patients with acute leukaemia: successful therapy with combination caspofungin and liposomal amphotericin B. Cancer 2003; 97: 1025-32.
184. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797-802.
185. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposo-mal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292-9.
186. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81: 320-6.
187. Kusuki S, Hashii Y, Yoshida H, et al. Antifungal prophy-laxis with micafungin in patients treated for childhood cancer. Pediatr Blood Cancer 2009; 53: 605-9.
188. Sawada A, Sakata N, Higuchi B, et al. Comparison of mi-cafungin and fosfluconazole as prophylaxis for invasive fungal infection during neutropenia in children undergoing chemotherapy and hematopoietic stem cell transplantation [in Japanese]. Rinsho Ketsueki 2009; 50: 1692-9.
189. Mehta PA, Vinks A, Filipovich A, et al. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transpl 2010; 16: 1458-62.
190. Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus li-posomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010; 29: 415-20.
191. Koo A, Sung L, Allen U, et al. Efficacy and safety of cas-pofungin for the empiric management of fever in neu-tropenic children. Pediatr Infect Dis J 2007; 26: 854-6.
192. Zaoutis TE, Jafri HS, Huang LM, et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009; 123: 877-84.
193. Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis 2004; 23: 1093-7.
194. Natarajan G, Lulic-Botica M, Rongkavilit C, et al. Ex-perience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005; 25: 770-7.
195. Groll AH, Attarbase A, Schuster FR, et al. Treatment with caspofungin in immunocompromised paediatric patient: a multicentre survey. J Antimicrob Chemother 2006; 57: 527-35.
196. Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: a substudy of a randomised double-blind trial. Pediatr Infect Dis 2008; 27: 820-6.
197. Ostrosky-Ziechner L, Kontoyiannis D, Raffalli J, et al. International, open-label, non-comparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory Candidemia. Eur J Clin Microbiol Infect Dis 2005; 24: 654-61.
198. Cesaro S, Giacchino M, Locatelli F, et al. Safety and effi-cacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect Dis 2007; 18 (7): 28.
199. Cesaro S, Toffolutti T, Messini C, et al. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur J Hematol 2004; 73: 50-5.
200. Sidhu MK, van Engen AK, Kleintjens J, et al. Cost-effec-tiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK. Curr Med Res Opin 2009; 25: 2049-59.
201. Wingard JR, Leather HL, Wood CA, et al. Pharma-coeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neu-tropenic fever. Am J Health Syst Pharm 2007; 64: 637-43.
202. Kaskel P, Tuschy S, Wagner A, et al. Economic evaluation of caspofungin vs liposomal amphotericin B for empiric therapy of suspected systemic fungal infection in the German hospital setting. Ann Hematol 2008; 87: 311-9.
203. Bruynesteyn K, Gant V, McKenzie C, et al. A cost-effec-tiveness analysis of caspofungin vs. liposomal amphote-ricin B for treatment of suspected fungal infections in the UK. Eur J Haematol 2007; 78: 532-9.
204. Zilberberg MD, Kothari S, Shorr AF. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation. Crit Care 2009; 13: R94.
205. Sohn HS, Lee T-J, Kim J, et al. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hemato-poietic stem cell transplantation in Korea. Clin Ther 2009; 31: 1105-15.